Nova Bay Pharmceuticals, Inc. NBY
We are going to want to keep an eye out for NBY this week. The stock saw a surge last week, and is scheduled to report earnings on Thursday. The company recently launched a line of anti-microbial disinfecting wipes for the face and eyes. This has a unique synergy with the current health crisis, as one of the piomary ways to help slow the spread of COVID-19 is to limit the germ exchange which takes place when touching your face, and then touching objects around you.
It seems evident that consideration for how a stock related to the sweeping pandemic which experts warn could persist for as much as 18 months, is going to have to be built into virtually every idea we look at for our reports for the foreseeable future.
Aytu BioScience, Inc. AYTU
We’ve been tracking AYTU for a couple of weeks now, beginning with our report from the morning of the 10th. We want to rehash our interest in this coronavirus related play as the company announces the official FDA distribution green light for its rapid point-of-care diagnostic test.
We already witnessed a huge run by AYTU since we’ve been covering it, which was later mitigated by a large public offering. However, we want to continue to stay hot on its trail in the wake of this morning’s news, which we’ll share below. The company expects the first shipment of 100,000 tests to be distributed presently, which is especially significant, considering that exceeds the total number of Amicans who have been tested so far, as the US lags behind almost every major country in that regard.
Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has received confirmation from the U.S. Food and Drug Administration (FDA) that the company may begin distribution of its Coronavirus Disease 2019 (“COVID-2019”) IgG/IgM Rapid Test throughout the United States. The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care. (>>Read Full PR)
Target Corp. TGT
We also want to quickly update readers on a longer-term options options idea we recently submitted, the TGT 04/03 $98-90 Puts. It’s a wide range of contracts and toward the end of last week, the first of those began being pushed into the money as TGT fell.
The total ranges are as follows on the $98 and $97 Puts, and we are going to want to continue to monitor the entire range between now and next Friday, because this idea may just be getting warmed up.
$98: 2.51-5.79 (+131%)
$97: 3.50-5.59 (+60%)
TLRY, CGC, CRON, AMRX